ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: FR-PO050

The Relationship Between Statin Use and 1-Year Mortality After Severe AKI

Session Information

Category: Acute Kidney Injury

  • 102 AKI: Clinical, Outcomes, and Trials


  • Wu, Chia-Lin, Changhua Christian Hospital, Changhua, Taiwan
  • Hsu, Chih-cheng, Institute of Population Health Sciences, National Health Research Institutes, Miaoli County, Taiwan
  • Tarng, Der-Cherng, Taipei Veteran's General Hospital, Taipei, Taiwan

The potential survival benefits of statin use in patients with dialysis-requiring acute kidney injury (AKI) are still not known. We examined the association between statin use and 1-year mortality in patients with dialysis-requiring AKI.


This nationwide population-based retrospective cohort study included 6091 hospitalized patients with dialysis-requiring AKI (1271 statin users and 4820 statin non-users) retrieved from the National Health Insurance Research Database of Taiwan between January 1, 2000, and December 31, 2012. All patients were followed up until December 31, 2013. Primary outcome was 1-year mortality after dialysis-requiring AKI. All primary analyses were performed using the intention-to-treat approach.


During the 1-year follow-up period, 492 of 1271 (38.7%) statin users and 2365 of 4820 (49.1%) statin non-users died after dialysis-requiring AKI. Statin use was independently associated with lower risks of 1-year all-cause mortality (hazard ratio [HR], 0.81; 95% confidence interval [CI], 0.73-0.91; p<0.001) and in-hospital all-cause mortality (HR, 0.82; 95% CI, 0.72-0.94; p=0.004). The survival benefit of statin treatment was dose-dependent and consistent across subgroups based on sensitivity analyses.


Statin use was independently associated with reduced risks of 1-year and in-hospital mortality in patients with dialysis-requiring AKI. However, further clinical trials are warranted to confirm our results.

Incidence and risk of 1-year mortality in patients with dialysis-requiring AKI
CohortsEvents (n/N)Incident rateCrude HR (95% CI)P valueAdjusted HR (95% CI)P value
Statin non-users2365/482068.7 (65.9–71.5)1 [Reference] 1 [Reference] 
Statin users492/127146.6 (42.4–50.7)0.71 (0.65–0.79)<0.0010.81 (0.73–0.91)<0.001
Stratified by cDDD      
cDDD <39266/65150.3 (44.3–56.4)0.77 (0.67–0.87)<0.0010.87 (0.76–0.99)0.04
cDDD >=39226/62042.8 (37.2–48.3)0.66 (0.58–0.76)<0.0010.75 (0.65–0.87)<0.001
P for trend   <0.001 <0.001

Incident rate: 1000 person-years

Kaplan-Meier curves for the cumulative incidences of all-cause mortality in statin users and non-users. cDDD = cumulative defined daily dose.